LBRX
LB Pharmaceuticals Inc (LBRX)
Healthcare • NASDAQ • $47.62+0.83%
- Symbol
- LBRX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $47.62
- Daily Change
- +0.83%
- Market Cap
- $1.54B
- Trailing P/E
- N/A
- Forward P/E
- -9.65
- 52W High
- $49.14
- 52W Low
- $13.36
- Analyst Target
- $51.50
- Dividend Yield
- N/A
- Beta
- N/A
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Company websiteResearch LBRX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.